Impact of Environmental Factors and Metabolomics on Colorectal Cancer.

Impact of Environmental Factors and Metabolomics on Colorectal Cancer Development and Prognosis Based on Environmental Factors and Metabolomics.

Colorectal cancer is one of the malignant tumours with high morbidity and mortality worldwide, posing a serious threat to human health. In recent years, the incidence of colorectal cancer has been on the rise with changes in lifestyle and dietary habits. Although some progress has been made in treatments such as surgery, chemotherapy and radiotherapy, however, the early diagnosis, prognosis assessment and personalised treatment of colorectal cancer still face great challenges. Therefore, it is of great academic value and practical significance to deeply explore the influencing factors of colorectal cancer occurrence, development and its prognosis, especially the research on environmental factors and metabolomics.

In this study, investigators collected clinical information, blood, urine and stool for ambient air pollution analysis, blood metabolomics analysis and stool macro-genetic sequencing by including patients from healthy control and colorectal cancer groups, respectively. Environmental factors, metabolomics and intestinal microbiota data were integrated and analysed to screen for indicators that play a key role in colorectal cancer development and construct a colorectal cancer prediction model.

Inclusion Criteria:

1. Healthy control group:

   • age ≥18 years old;
   • no history of malignant tumour;
   • willing to participate in this study and sign the informed consent form;
   • complete basic data.

2. Gastric cancer group:

   • age ≥18 years old;
   • patients diagnosed with gastric cancer by pathological biopsy before operation;
   • no chemotherapy, radiotherapy, targeted and immunotherapy before enrolment;
   • willing to participate in this study and sign the informed consent; complete clinical data.

Exclusion criteria:

• patients with primary malignant tumours other than gastric cancer;
• patients with serious cardiopulmonary insufficiency and other systemic diseases that affect the choice of treatment plan;
• patients who are not suitable for enrolment as assessed by the investigator.